Bacterial Vaginosis

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged TreatmentReadmore

Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Despite being the most common vaginal condition, BV symptoms are often mistaken for a yeast infectionReadmore

Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosis

Gedea Biotech developing antibiotic-free treatments, today announced that the Swedish Medical Product Agency and Ethics committee have approved the initiation of a randomized, partly-blinded investigation to evaluate the clinical performance and safety ofReadmore

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisReadmore

Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infections

Swedish women’s health company Gedea Biotech announced today that EPO has granted patent for its Glucone-delta lactone (GDL) in pHyphReadmore